An Extension to Study MD7108240

Status:
Completed

Trial end date:
2009-09-09

Target enrollment:

Participant gender:

This is a two month study to allow continued treatment with pazopanib eye drops. Study may be extended to 5 months.

Phase 2

GlaxoSmithKline